Daedalus Angel Syndicate
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Daedalus Collective
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Dai-ichi Life Insurance Company
Based on the provided information, it's difficult to formulate a comprehensive investment thesis and strategy description for Dai-ichi Life Insurance Company as a VC firm. The data suggests that Dai-ichi Life engages in venture capital activities, but the scope and scale of those activities are not explicitly outlined in the crawled web pages. Their VC activities are evident from the 2008 news release regarding the "ベンチャーキャピタル事業における共同事業の強化について" (Strengthening of joint projects in the venture capital business). However, details on specific investment areas, target companies, or the firm's overall investment approach are lacking from the available information. From the news releases, they appear to be investing in funds and projects related to healthcare, elderly care, and other social welfare-related sectors.
Damgaard Co.
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Danieli
Based on the provided content, it is difficult to determine the firm's overall investment thesis and strategy as Maddyness appears to be primarily a news media outlet covering the French tech and startup ecosystem. The portfolio section of Maddyness highlights various startups and funds, but it doesn't explicitly outline Danieli's investment philosophy or approach. We can infer that their strategy likely involves early-stage investing given the focus on startups. However, without more information, it's impossible to provide a detailed summary. Maddyness is dedicated to helping entrepreneurs find the right investor by providing portraits of different funds. This suggests an informational role rather than a direct investment summary.
Danish BioInnovation Institute
Danish BioInnovation Institute (BII) is a venture capital firm focused on supporting early-stage start-ups and spin-out companies within human health, planetary health, and societal resilience. They aim to translate scientific breakthroughs into innovative products and solutions. BII provides funding, lab and office space, and comprehensive support to help entrepreneurs accelerate their journey towards validated ventures and company creation. Their programs include Venture Lab, Bio Studio, and Quantum Lab, each tailored to specific stages and areas of innovation. They actively foster a community where scientific discoveries can be transformed into viable businesses, contributing to a better world by addressing pressing global challenges in health and sustainability. They provide access to state-of-the-art laboratories, resources, and support systems to ensure their portfolio companies have the environment to thrive and develop cutting-edge technologies and solutions. BII operates through a series of focused programs designed to support start-ups at various stages. The Venture Lab program is for early-stage start-ups providing up to DKK 4M in funding to accelerate venture validation. The Bio Studio program supports entrepreneurial academic researchers in translating their science into innovative products and solutions, offering up to DKK 5.35M funding per year for three years. The Quantum Lab focuses on early-stage quantum technology startups in collaboration with NATO DIANA. In addition to funding, BII provides access to fully equipped laboratories, office spaces, and other essential infrastructure, allowing companies to focus on their research and development. BII's approach extends beyond mere financial investment. They provide extensive support services, including waste management, access to basic laboratory gases, consumables, and equipment, autoclaving and dishwashing services, and cryo/freezer storage space. They also assist with regulatory compliance, such as advising on work related to genetically modified organisms. This holistic support system is designed to minimize operational burdens and maximize the efficiency of their portfolio companies. By combining funding, facilities, and expertise, BII aims to create an ecosystem where innovation can flourish and impactful solutions can be developed and brought to market. BII demonstrates its commitment to creating societal impact through focusing its investments in areas critical to the future, such as human health, planetary health, and societal resilience. This is further supported by their collaborative environment in which portfolio companies can collaborate and leverage on shared knowledge and facilities. This is enhanced by the dedicated program support, specifically tailored to the needs of the different stages of growth and innovation. In addition, BII provides access to expert guidance, equipment, and facilities that enable the development and validation of novel technologies. By actively seeking and supporting changemakers, BII fosters an ecosystem conducive to the growth of innovative start-ups and spin-outs capable of addressing complex global challenges. They have achieved substantial traction, having supported 131 start-ups to date and contributing to the launch of 21 products on the market. With €139M in total funding and a portfolio that has collectively raised €1B in external funding, BII underscores its role as a significant catalyst for bioinnovation and a valuable partner for entrepreneurs seeking to translate scientific ideas into tangible solutions.
Danish Export and Investment Fund (EIFO)
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Danish Growth Fund
Støtter danske virksomheder i at skabe vækst, innovere og bidrage til samfundsmæssige udfordringer som grøn omstilling, forsvar og global konkurrenceevne. Fokus på at skabe jobs, bidrage til BNP og skatteindtægter.
Danish Industry Foundation (Industriens Fond)
Industriens Fond (the Danish Industry Foundation) supports projects that benefit Danish companies. Their primary focus is on creating and applying new knowledge within the Danish business sector, viewing it as a fundamental driver for growth. They aim to ensure companies have access to employees with the necessary knowledge and skills to foster growth, emphasizing the importance of innovation to empower SMEs and entrepreneurs, granting them access to new markets and opportunities. The foundation achieves this through providing knowledge, developing competencies and fostering innovation in Danish businesses.
Dansk Vækstkapital
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Danstar Ferment
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Darco Capital
A founder-first fund focused on supporting founders in scaling their businesses, leveraging David Adelman’s operational experience in student housing and alternative asset management.
Daring Capital
Daring Capital invests in extraordinary underrepresented founders building companies that make the world a better place. They focus on mission-led startups often overlooked by traditional investors due to lack of track record or access to wealthy networks. The firm emphasizes transparency, agility, and founder-centric support to drive impact and profitability.
Darwazah Capital
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Datascience Service
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Davidson Kempner
Davidson Kempner Capital Management LP is a global investment management firm with over 40 years of experience focusing on fundamental investing with a multi-strategy approach. Their investment approach is global and opportunistic with a focus on credit and event-driven situations. They emphasize discipline and acumen honed over decades and tackle complex transactions. They look to build deep local networks in markets where they invest and they are committed to generating long-term value for investors. They actively invest in the Middle East and see significant opportunities in the asset-based finance (ABF) sector. They have been an active investor in the Middle East for over a decade. Davidson Kempner identifies opportunities in private asset-based finance, where credit is secured by assets and structural protections mitigate downside risk. They are active in U.S. second-lien residential mortgage lending, European SME asset-based lending, and U.S. mid-ticket equipment finance. They see structural complexity, regulatory shifts, and limited competition as opportunities for private lenders. The firm recognizes the evolving role of traditional bank lenders and their partnerships with non-bank lenders due to regulatory capital requirements. They focus on collateral-backed financing that expands access to credit at a lower cost while leveraging ABF's structural protections to mitigate risk. The firm views the expansion into the Middle East (Abu Dhabi office) as a way to harness global investment expertise and target diverse investment opportunities. This office marks a natural extension of their presence in the region, deepening their reach and the accessibility of their capital to different local businesses.
Dawn Biopharma
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
De Nora
Invests in early-stage technologies and startups in electrochemical, water treatment, and energy transition sectors to drive strategic innovation and sustainable growth.
DeBa Ventures
DeBa Ventures is a venture capital firm focused on discovering, supporting, and promoting founders crafting the future of fintech. They are more than just investors; they aim to be partners in shaping the future of the fintech industry by seeking out passionate entrepreneurs solving real-world problems through innovation. The firm emphasizes a founder-driven approach, leveraging the experience of their team, which includes successful exited entrepreneurs and seasoned fund managers. They provide tailored mentorship and strategic support, recognizing the unique challenges startups face. DeBa Ventures offers flexible investment models and fosters a collaborative partnership through their network of experts and advisors, combined with regular strategic sessions. Their investment strategy is global and prioritizes fintech companies, along with B2B, AI and SaaS, reflecting a commitment to fostering innovation in these dynamic sectors without geographical limitations. They believe in nurturing innovation and building a collaborative journey with visionary founders. The firm's mission is to uncover, nurture, and elevate the entrepreneurs shaping the future. DeBa Ventures distinguishes itself with a unique shared success model, allocating 10% of their profits back to the employees of their portfolio companies, acknowledging their contributions to collective achievements and growth. This policy reflects their belief in rewarding dedication and hard work, creating a mutually beneficial partnership. They measure their achievements by the great entrepreneurs they partner with, highlighting their portfolio's forward-looking companies.
Dealflow.eu Ventures EU
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Debiopharm Innovation Fund
Debiopharm Innovation Fund invests in digital health and smart data start-ups with the aim to improve patient outcomes and quality of life, particularly in oncology and infectious diseases. They seek to establish tomorrow's standard of care by enabling innovation in drug development, drug manufacturing, and digital health. The fund focuses on companies applying AI and data-driven insights to accelerate clinical trials, improve patient outcomes, and enhance drug discovery. They aim to leverage new imaging digital biomarkers from longitudinal images to help Debiopharm accelerate time to market and improve success rates of clinical trials, and are exploring digital twins for use in virtual control arms. The fund invests in areas that can significantly reduce the time and costs of clinical trials, more accurately predict patient outcomes, or enhance drug discovery using AI and data analytics. They are interested in platforms that can acquire imaging data from trial sites and generate clinically meaningful predictions from imaging data. Additionally, they seek opportunities in areas like collaborative software platforms for expanded access to medicines, cancer data aggregation and analytics platforms for precision oncology, and privacy-preserving data collaboration platforms. Debiopharm's investment strategy is driven by a desire to positively contribute to society and the environment through corporate responsibility. The fund supports projects and works that aim at improving the quality of life for patients. They actively seek out entrepreneurs with ambitions to take their professional endeavors to the next level and provide funding and support to help them achieve their goals. They appear to be interested in solutions related to in-vivo study design, AI-driven data cleaning, precision medicine in radiology, AI for clinical teams and multimodal AI models for histology images.
Decasonic
Decasonic is a venture and digital assets fund focused on building blockchain and AI innovation. They invest in early-stage companies in the Web3 and AI supercycle, emphasizing a product-first and thesis-driven approach. The firm aims to partner closely with founders building durable companies through periods of technological and market change. They draw on decades of experience as tech investors and operators to help founders in blockchain accelerate product-market fit and scale growth. The firm believes that blockchain and AI are at a similar stage as the internet in 2000 and that tomorrow's killer apps represent trillion-dollar opportunities. Decasonic seeks to partner with outlier founders who generate 100x+ outcomes. They operate like outlier founders, demonstrating dedication to building blockchain and AI innovation.
Decathlon Pulse
Based on the limited crawled page, Decathlon Pulse's investment thesis seems to revolve around partnering with companies that are 'changing the game'. However, without further information on their investment focus, specific sectors, and stage preferences, it is difficult to provide a comprehensive investment thesis. The imagery suggests an association with sports, fitness, or outdoor activities.
Decelera Ventures
Decelera Ventures is a founder-centric venture capital fund that invests in mission-driven founders with the potential to build transformative, sustainable companies. They operate a 'startup decelerator,' focusing on providing early-stage ventures with the tools and support to unlock their full potential. Their investment approach centers on the people behind the companies, emphasizing resilience, vision, and leadership. Decelera aims to create a profound and lasting impact on both companies and founders, empowering them to grow and thrive in a competitive market. Decelera's strategy involves a unique program located in Menorca, Spain, designed to foster purposeful growth. The program helps founders validate their business models while providing deep insights into their team’s potential and readiness to scale. The firm believes that growth requires more than just capital, and their program acts as a personal and professional oasis for founders, focusing on community support and local ecosystem development. The firm is committed to supporting local and emerging ecosystems, contributing to tier two and three economies. They actively engage with the local community by partnering with public schools to offer entrepreneurship training to children and teenagers. The fund aims to build a global ecosystem of mission-driven entrepreneurs who address critical environmental and social challenges, fostering innovations that create a more sustainable world. Decelera combines visionary thinking with measurable results to ensure lasting impact. They are proactive and solution-oriented, tackling challenges with teamwork and encouraging collaboration. Their values include open communication, honesty, mutual respect, integrity, and transparency. They also aim for excellence and embrace constant improvement, fostering a professional yet enjoyable environment.